Nichi-Iko Has An Ally In Argentina On Infliximab
Strikes Deal With Laboratorio Elea To Market Remicade Biosimilar
Executive Summary
Laboratorio Elea has struck a deal with Nichi-Iko Pharmaceutical to market the Japanese firm’s infliximab biosimilar in Argentina.